AOD-9604

AOD-9604 is the C-terminal fragment of human growth hormone, residues 176-191, a hexadecapeptide in which the native N-terminal phenylalanine is substituted for tyrosine. The substitution is structurally trivial — an added hydroxyl on the aromatic ring — but it improved stability and allowed precise tracking in trials. AOD stands for Anti-Obesity Drug, reflecting development by Metabolic Pharmaceuticals in Australia through the 1990s, following work at Monash University.

The design intent was dissociation of hGH's lipolytic activity from its somatogenic and diabetogenic activity: fat mobilisation without insulin resistance, fluid retention, IGF-1 elevation, carpal tunnel, or organomegaly.

Clinical development was extensive by research-peptide standards: six randomised, double-blind, placebo-controlled human trials, over 900 participants, all using oral tablets. Phase 2a (2001-2004, approximately 300 obese adults, 12 weeks) showed 2.6 kg loss at 1 mg versus 0.8 kg on placebo, but with an inverted dose-response curve across 1, 5, 10, 20 and 30 mg. The Phase 2b OPTIONS study (2006-2007, 536 obese adults, BMI 30-45, 24 weeks, 0.25/0.5/1 mg) missed its primary endpoint at every dose; the sponsor judged the effect "too low to support commercial development" and terminated the programme in 2007. An earlier Phase 2a report describes 54 obese subjects over 12 weeks with the same 2.6 kg versus 0.8 kg result.

Heffernan et al. (2001) confirmed using HGH-receptor-transfected cells that AOD-9604 does not compete for growth hormone receptor binding and does not induce receptor-mediated proliferation — the structural basis for its lack of IGF-1, glycaemic and anabolic effects.

Distinguish it from unmodified HGH Fragment 176-191, which retains N-terminal phenylalanine, lacks the stabilising substitution, and has zero human data; all claims made for it are extrapolated from AOD-9604.

Regulatory position: not FDA approved as a drug, GRAS status granted for food applications, and in December 2024 the FDA's Pharmacy Compounding Advisory Committee recommended against inclusion on the 503A Bulk Drug Substances List. WADA prohibits it under S2.2.3.

Formulation note: it aggregates and gels more aggressively than any other common research peptide. Reconstitute in 0.6% acetic acid, not bacteriostatic water.

AOD-9604 stimulates adipocyte lipolysis through beta-3 adrenergic receptor signalling, which activates hormone-sensitive lipase and hydrolyses stored triglyceride to free fatty acids and glycerol.

The mechanism appears to be permissive rather than direct. Heffernan et al. (2001) treated wild-type and beta-3 AR knockout mice for 14 days: wild-type animals showed reduced body weight gain and increased lipolysis, knockouts did not respond, establishing beta-3 ARs as required for the chronic lipolytic effect. The same work showed both hGH and AOD-9604 upregulated beta-3 AR RNA expression in obese mice to levels comparable with lean mice. Taken together, the compound appears to upregulate beta-3 AR expression and prime adipocytes for enhanced sensitivity to other lipolytic signals rather than acting as a direct receptor agonist. Earlier characterisation of the fragment also describes inhibition of lipogenesis, blocking conversion of carbohydrate into triglycerides and fatty acids, with preferential activity at high-fat-deposit sites.

Negative pharmacology is the defining feature. No growth hormone receptor binding, no IGF-1 elevation, no effect on glucose or insulin sensitivity, no appetite suppression, no anabolic, sleep, recovery or anti-ageing signal.

Mechanistically it is also unrelated to the incretins. Semaglutide, tirzepatide and retatrutide act centrally via GLP-1, GIP and glucagon receptor signalling, slowing gastric emptying and altering hunger and satiety processing. AOD-9604 acts peripherally on the adipocyte and does not meaningfully affect hunger.

The reason the mechanism underdelivers is that it reproduces only part of one of two GH pathways. GH exerts a direct lipolytic effect via hormone-sensitive lipase, amplified during fasting as insulin falls and GH becomes the dominant metabolic regulator (Sakharova et al., 2008). It then converts hepatically to IGF-1, which activates hormone-sensitive lipase again while driving muscle protein synthesis, recovery, collagen production, bone density and cognitive function. A secretagogue such as CJC-1295 with Ipamorelin, or Tesamorelin, triggers the complete cascade. AOD-9604 supplies a weaker isolated version of step one.

Pharmacokinetics: intravenous half-life of approximately 3 minutes in animals, with rapid degradation by N-terminal amino acid removal. Oral bioavailability in rats is approximately 40%. The short half-life underpins daily fasted dosing.

Lipid metabolism: stimulates lipolysis in adipose tissue and may increase fat oxidation. In obese mice, both AOD-9604 and full-length GH reduced body weight after 14 days of chronic intraperitoneal injection, with increased fat oxidation and raised plasma glycerol and no adverse effect on glucose or insulin. In Zucker rats, 19 days of oral dosing at 500 mcg/kg reduced body weight gain by over 50% versus controls. Inhibition of lipogenesis and preferential action at high-fat-deposit regions are also attributed to the fragment, and some practitioners administer it near stubborn deposits on the basis of a possible local effect — speculative and unproven in controlled trials.

Glycaemic and endocrine neutrality: no growth hormone receptor binding, no change in serum IGF-1, no impact on glucose metabolism or insulin sensitivity, no water retention. This is the basis for layering it onto a GLP-1 protocol without opposing glycaemic effects, and it is the relevant distinction from full-length hGH and from the GHRH analogues, which are counter-regulatory to insulin.

Musculoskeletal: Kwon and Park (2015) reported enhanced cartilage regeneration from weekly intra-articular injections of 0.25 mg for 4 to 7 weeks in a rabbit osteoarthritis model, with the AOD-9604 plus hyaluronic acid combination outperforming either agent alone. Bone and cartilage repair, bone strength, anti-inflammatory activity in arthritis, joint flexibility and mobility, and prevention of medication-related muscle wasting are all attributed to the fragment, but the joint evidence is a single preclinical study with no human trials.

Dermal: enhanced collagen production and skin elasticity have been attributed to it.

Clinical positioning in practice is as an adjunct or plateau-breaker on top of diet, training and a GLP-1 regimen. The honest reading of the human data is that any contribution is marginal, and that it is largely redundant alongside a growth hormone secretagogue, which produces the same lipolytic signalling through the full GH-to-IGF-1 cascade.

Expectations should be calibrated against the trial record, not the marketing.

Phase 2a (12 weeks, approximately 300 obese adults, oral tablets, six dose groups): 2.6 kg loss in the 1 mg arm versus 0.8 kg on placebo, statistically significant but with an inverted dose-response curve across 1 to 30 mg — a pattern consistent with noise as much as with a genuine drug effect. Phase 2b OPTIONS (24 weeks, 536 obese adults, BMI 30-45, 0.25/0.5/1 mg): no statistically significant weight loss versus placebo at any dose, and the trial that ended development in 2007.

All six human trials used oral tablets. Subcutaneous injection, the route used in practice today, was never tested in any of them, and oral bioavailability limitations may have blunted the trial results. Whether injection improves outcomes is unknown rather than established.

Reported experience is split. Subtle midsection fat reduction over 6 to 12 weeks of daily subcutaneous dosing in some users; no perceptible change after full cycles in others. The recurring characterisation is a "50/50 shot". It functions better as a marginal edge for those with diet and training already dialled in than as a primary intervention for someone with substantial fat to lose. It does not produce incretin-grade body composition change, nor the change seen from a well-run secretagogue protocol or a well-managed caloric deficit.

No appetite suppression, no sleep or recovery signal, no anabolic effect.

Redundancy is the main practical caveat. On a protocol already containing CJC-1295 and Ipamorelin or Tesamorelin, endogenous GH is already driving hormone-sensitive lipase directly and converting to IGF-1 for the indirect lipolytic and anabolic arms. AOD-9604 layered on top duplicates a fragment of the first arm only.

Tolerability: most users report nothing. Occasional mild injection site reactions, headache, mild nausea and indigestion, consistent with the placebo-equivalent adverse event profile in the trials. The most common practical complaint by a wide margin is gelling in the vial, not a physiological side effect.

Any narrow case for use sits with people who cannot use a secretagogue or a GLP-1, want low cost and low risk, and hold fully realistic expectations.

Studied doses were oral: 0.25 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 20 mg and 30 mg daily, with two pilot studies using intravenous administration. There are no published dose-finding data for subcutaneous injection, the route used in practice. The protocols below reflect practice patterns only.

Standard: 300 mcg once daily, subcutaneous, first thing in the morning fasted, with at least 30 minutes before food. Higher dose: 500 mcg once daily fasted, sometimes split as 250 mcg on waking plus 250 mcg before bed. Cycle length 4 to 12 weeks, commonly followed by an off period of equal length.

Rationale for fasted administration: as a peptide fragment, food in the system may interfere with absorption and effectiveness, and morning dosing coincides with the fasted state in which GH-mediated lipolysis is physiologically dominant. Given an intravenous half-life of roughly 3 minutes, peak exposure is brief and daily consistency matters more than precise timing beyond the fasted window.

Reconstitution is non-negotiable and differs from every other common peptide. Do not use bacteriostatic water alone. Three structural features drive aggregation: roughly six of the 16 residues are hydrophobic and cluster to escape the aqueous phase; the two cysteines are joined by a disulfide bond that, once broken, allows intermolecular sulfur cross-linking into visible chains; and agitation generates air-to-liquid interfaces at which hydrophobic domains orient toward air, unfolding the molecule and causing aggregation as bubbles collapse. The three mechanisms feed each other.

Use 0.6% acetic acid. It protonates the peptide, strengthening its net positive charge so like-charged molecules repel rather than cluster, and it slows sulfur bonding after disulfide cleavage.

Preferred method: 2 mL of 0.6% acetic acid added slowly down the inside vial wall, never sprayed onto the powder, no shaking, allowed to dissolve unassisted over several minutes, swirled gently only if required. Alternative: 1 mL of 0.6% acetic acid plus 1 mL bacteriostatic water — acid first, allow dissolution to begin, then bacteriostatic water down the wall; the acid provides pH reduction for stability while the bacteriostatic water contributes benzyl alcohol as preservative.

Draw volumes, 5 mg vial in 2 mL (2.5 mg/mL, 2500 mcg/mL): 250 mcg = 0.10 mL = 10 units; 300 mcg = 0.12 mL = 12 units; 500 mcg = 0.20 mL = 20 units. Vial duration approximately 16 days at 300 mcg/day, 10 days at 500 mcg/day. A 1 mL reconstitution (5 mg/mL) gives 5, 6 and 10 units respectively — workable but with volumes too small for precise measurement.

Preload syringes after reconstitution. Each stopper puncture and draw introduces agitation, so a single disturbance is preferable to daily ones.

Storage: lyophilised powder at -4F (-20C) or refrigerated, protected from light; reconstituted vials at 36 to 46F (2 to 8C), used within 28 days, never frozen.

Acceptable versus unacceptable appearance: gradual gelling over time occurs even with correct technique, and some sources hold that gelled material remains functional. A glob that never dissolves from day one together with a thick, milky solution indicates degradation before arrival, manufacturing failure, or contamination during reconstitution — discard and request replacement.

Rotate sites daily, abdomen most commonly used. Do not aspirate for subcutaneous injection. Prohibited in tested sport under WADA S2.2.3.

The human dataset is unusually large for a research peptide and unusually unflattering. Six randomised, double-blind, placebo-controlled trials with over 900 participants were completed by Metabolic Pharmaceuticals Ltd.

Phase 2a (2001-2004): approximately 300 obese adults, oral tablets once daily for 12 weeks across six arms (1, 5, 10, 20, 30 mg and placebo). The 1 mg group lost 2.6 kg (5.7 lb) versus 0.8 kg (1.8 lb) on placebo — statistically significant, but with an inverted dose-response curve in which the lowest dose outperformed all higher doses, raising the question of drug effect versus noise.

Phase 2b, the OPTIONS study (2006-2007): 536 obese adults, BMI 30-45, oral tablets once daily for 24 weeks at 0.25, 0.5 and 1 mg plus placebo. The primary endpoint of weight loss versus placebo failed at every dose. The sponsor judged the results too low to support commercial development and terminated the obesity programme in 2007.

Mechanistic preclinical work: Heffernan et al. (2001, Endocrinology) treated normal and beta-3 adrenergic receptor knockout mice for 14 days. Normal mice showed reduced body weight gain and increased lipolysis; knockout mice did not respond, establishing that beta-3 ARs are required for chronic lipolytic effect. Both hGH and AOD-9604 raised beta-3 AR RNA expression in obese mice to lean-mouse levels, suggesting the action is indirect — upregulating receptor expression and priming adipocyte sensitivity rather than binding the receptor directly. The same work confirmed AOD-9604 does not compete for binding at the hGH receptor and does not induce proliferation through it, which explains the absence of IGF-1 and glycaemic effects. In Zucker rats, 19 days of oral dosing at 500 mcg/kg body weight reduced weight gain by over 50% versus controls.

Cartilage: Kwon and Park (2015) gave weekly intra-articular injections of 0.25 mg for 4 to 7 weeks in a rabbit osteoarthritis model, with enhanced cartilage regeneration and greater effect when combined with hyaluronic acid. Single preclinical study; no human trials for this indication.

Pharmacokinetics and safety: intravenous half-life in animals is approximately 3 minutes, with rapid degradation by N-terminal amino acid removal; oral bioavailability in rats is roughly 40%. Aggregated safety showed no effect on serum IGF-1, no impact on glucose metabolism or insulin sensitivity, no anti-AOD-9604 antibodies, and no serious adverse events. Toxicology NOAEL was 100 mg/kg/day in rats and 50 mg/kg/day in monkeys. GRAS status was granted for food applications; the FDA Pharmacy Compounding Advisory Committee recommended against 503A bulks listing in December 2024.

The decisive limitation: all six human trials used oral tablets. Subcutaneous injection, the route used in practice, has never been tested in a human dose-finding study, so no published data establishes optimal injectable dosing.